JP2019520034A5 - - Google Patents

Download PDF

Info

Publication number
JP2019520034A5
JP2019520034A5 JP2018550322A JP2018550322A JP2019520034A5 JP 2019520034 A5 JP2019520034 A5 JP 2019520034A5 JP 2018550322 A JP2018550322 A JP 2018550322A JP 2018550322 A JP2018550322 A JP 2018550322A JP 2019520034 A5 JP2019520034 A5 JP 2019520034A5
Authority
JP
Japan
Prior art keywords
seq
antigen
antibody
human
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018550322A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019520034A (ja
JP7491666B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2017/059071 external-priority patent/WO2017178653A2/en
Publication of JP2019520034A publication Critical patent/JP2019520034A/ja
Publication of JP2019520034A5 publication Critical patent/JP2019520034A5/ja
Priority to JP2022112873A priority Critical patent/JP7549626B2/ja
Application granted granted Critical
Publication of JP7491666B2 publication Critical patent/JP7491666B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018550322A 2016-04-14 2017-04-14 新規な抗SIRPa抗体およびそれらの治療適用 Active JP7491666B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022112873A JP7549626B2 (ja) 2016-04-14 2022-07-14 新規な抗SIRPa抗体およびそれらの治療適用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662322707P 2016-04-14 2016-04-14
US62/322,707 2016-04-14
EP17305182.2 2017-02-17
EP17305182 2017-02-17
PCT/EP2017/059071 WO2017178653A2 (en) 2016-04-14 2017-04-14 NEW ANTI-SIRPa ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022112873A Division JP7549626B2 (ja) 2016-04-14 2022-07-14 新規な抗SIRPa抗体およびそれらの治療適用

Publications (3)

Publication Number Publication Date
JP2019520034A JP2019520034A (ja) 2019-07-18
JP2019520034A5 true JP2019520034A5 (enExample) 2020-05-21
JP7491666B2 JP7491666B2 (ja) 2024-05-28

Family

ID=65529144

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018550322A Active JP7491666B2 (ja) 2016-04-14 2017-04-14 新規な抗SIRPa抗体およびそれらの治療適用
JP2022112873A Active JP7549626B2 (ja) 2016-04-14 2022-07-14 新規な抗SIRPa抗体およびそれらの治療適用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022112873A Active JP7549626B2 (ja) 2016-04-14 2022-07-14 新規な抗SIRPa抗体およびそれらの治療適用

Country Status (24)

Country Link
US (3) US11279766B2 (enExample)
EP (1) EP4438626A3 (enExample)
JP (2) JP7491666B2 (enExample)
KR (1) KR102355240B1 (enExample)
CN (1) CN115785272A (enExample)
CL (1) CL2018002898A1 (enExample)
DK (1) DK3443010T3 (enExample)
ES (1) ES2990971T3 (enExample)
FI (1) FI3443010T3 (enExample)
HR (1) HRP20241316T1 (enExample)
HU (1) HUE068840T2 (enExample)
IL (1) IL262251B2 (enExample)
LT (1) LT3443010T (enExample)
MA (1) MA44665B1 (enExample)
MD (1) MD3443010T2 (enExample)
MX (1) MX2018012434A (enExample)
PH (1) PH12018550160B1 (enExample)
PL (1) PL3443010T3 (enExample)
RS (1) RS66062B1 (enExample)
SA (1) SA518400237B1 (enExample)
SI (1) SI3443010T1 (enExample)
SM (1) SMT202400438T1 (enExample)
UA (1) UA126658C2 (enExample)
ZA (1) ZA201806293B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20241316T1 (hr) * 2016-04-14 2024-12-20 Ose Immunotherapeutics Nova anti-sirpa antitijela i njihove terapijske primjene
JOP20190009A1 (ar) 2016-09-21 2019-01-27 Alx Oncology Inc أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
PL3658589T3 (pl) * 2017-07-26 2024-03-18 Forty Seven, Inc. Przeciwciała anty-sirp-alfa i powiązane sposoby
US11713356B2 (en) 2017-10-13 2023-08-01 Ose Immunotherapeutics Modified bifunctional anti-human signal regulatory protein alpha (SIRPa) antibody and method of use thereof for treating cancer
WO2019175218A1 (en) 2018-03-13 2019-09-19 Ose Immunotherapeutics Use of anti-human sirpa v1 antibodies and method for producing anti-sirpa v1 antibodies
EP3768314A4 (en) 2018-03-21 2022-01-05 ALX Oncology Inc. ANTIBODIES AGAINST ALPHA SIGNAL REGULATING PROTEIN AND METHODS OF USE
TW202028237A (zh) 2018-09-27 2020-08-01 美商西建公司 SIRPα結合蛋白及其使用方法
US11591390B2 (en) 2018-09-27 2023-02-28 Celgene Corporation SIRP-α binding proteins and methods of use thereof
KR102902719B1 (ko) 2019-10-18 2025-12-24 포티 세븐, 엘엘씨 골수이형성 증후군 및 급성 골수성 백혈병을 치료하기 위한 조합 치료
CA3153636A1 (en) 2019-10-31 2021-05-06 Forty Seven, Inc. Anti-cd47 and anti-cd20 based treatment of blood cancer
CN112574310B (zh) * 2020-12-11 2023-05-05 浙江博锐生物制药有限公司 抗SIRPα抗体及其用途
KR102896511B1 (ko) * 2022-09-07 2025-12-08 주식회사 시프트바이오 SIRPα 변이체에 특이적으로 결합하는 항체

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
WO2001040307A1 (de) 1999-11-30 2001-06-07 Eberhard-Karls-Universität Tübingen Universitätsklinikum Antikörper gegen signal-regulator-proteine
US8613922B2 (en) * 2003-04-24 2013-12-24 The University Of North Carolina At Chapel Hill Methods for inhibiting diabetic retinopathy with an antibody against integrin associated protein (IAP)
US20100215640A1 (en) 2003-04-24 2010-08-26 The University Of North Carolina At Chapel Hill Method for inhibiting cellular activation by insulin-like growth factor-1
JP3936673B2 (ja) 2003-06-02 2007-06-27 国立大学法人群馬大学 Cd47部分ペプチドと抗shps−1モノクロナール抗体
CA2612241C (en) 2005-07-01 2018-11-06 Medarex, Inc. Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
ATE542830T1 (de) 2006-12-04 2012-02-15 Pasteur Institut Als gerüst verwendeter ob-fold zur entwicklung neuer spezifischer bindemittel
EP2573112A1 (en) 2007-10-11 2013-03-27 The Hospital For Sick Children Modulation of sirpa - cd47 interaction for increasing human hematopoietic stem cell engraftment and compounds therefor
CA2917512C (en) 2007-10-12 2025-08-05 President And Fellows Of Harvard College VACCINE NANOTECHNOLOGY
PT2242512T (pt) 2008-01-15 2016-07-18 Univ Leland Stanford Junior Métodos para manipular a fagocitose mediada por cd47
EP2111869A1 (en) 2008-04-23 2009-10-28 Stichting Sanquin Bloedvoorziening Compositions and methods to enhance the immune system
EP4209510B1 (en) 2008-12-09 2024-01-31 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
EP4311863A3 (en) 2009-05-15 2024-04-10 University Health Network Compositions and methods for treating hematologic cancers targeting the sirp alpha- cd47 interaction
GB201015765D0 (en) 2010-09-21 2010-10-27 Immatics Biotechnologies Gmbh Use of myeloid cell biomarkers for the diagnosis of cancer
EP3682896A1 (en) 2011-04-28 2020-07-22 University of Southern California Human myeloid derived suppressor cell cancer markers
JP2014519338A (ja) * 2011-06-16 2014-08-14 ノバルティス アーゲー 治療薬として使用される可溶性タンパク質
US20140242095A1 (en) * 2011-10-19 2014-08-28 University Health Network Antibodies and antibody fragments targeting sirp-alpha and their use in treating hematologic cancers
US9624298B2 (en) 2011-11-28 2017-04-18 Merck Patent Gmbh Anti-PD-L1 antibodies and uses thereof
JP6460796B2 (ja) 2012-01-17 2019-01-30 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 高親和性sirp−アルファ試薬
JP2016507555A (ja) 2013-02-06 2016-03-10 インヒブルクス エルピー 血小板非減少性かつ赤血球非減少性cd47抗体及びその使用方法
EP3757130A1 (en) 2013-09-26 2020-12-30 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
WO2015138600A2 (en) 2014-03-11 2015-09-17 The Board Of Trustees Of The Leland Stanford Junior University Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies
CN105085679B (zh) * 2014-04-25 2019-01-11 上海津曼特生物科技有限公司 全人源抗rankl抗体
EP3012271A1 (en) 2014-10-24 2016-04-27 Effimune Method and compositions for inducing differentiation of myeloid derived suppressor cell to treat cancer and infectious diseases
WO2016205042A1 (en) 2015-06-16 2016-12-22 The Board Of Trustees Of The Leland Stanford Junior University SIRPα AGONIST ANTIBODY
WO2017068164A1 (en) 2015-10-21 2017-04-27 Ose Immunotherapeutics Methods and compositions for modifying macrophage polarization into pro-inflammatory cells to treat cancer
HRP20241316T1 (hr) * 2016-04-14 2024-12-20 Ose Immunotherapeutics Nova anti-sirpa antitijela i njihove terapijske primjene
EP3443010B1 (en) 2016-04-14 2024-08-07 Ose Immunotherapeutics New anti-sirpa antibodies and their therapeutic applications
JOP20190009A1 (ar) 2016-09-21 2019-01-27 Alx Oncology Inc أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
CN110325549B (zh) 2016-12-09 2024-03-08 艾利妥 抗SIRPα抗体及其使用方法
WO2018190719A2 (en) * 2017-04-13 2018-10-18 Aduro Biotech Holdings, Europe B.V. Anti-sirp alpha antibodies
WO2018210795A1 (en) 2017-05-16 2018-11-22 Synthon Biopharmaceuticals B.V. ANTI-SIRPα ANTIBODIES
PL3658589T3 (pl) 2017-07-26 2024-03-18 Forty Seven, Inc. Przeciwciała anty-sirp-alfa i powiązane sposoby
US11713356B2 (en) 2017-10-13 2023-08-01 Ose Immunotherapeutics Modified bifunctional anti-human signal regulatory protein alpha (SIRPa) antibody and method of use thereof for treating cancer
WO2019175218A1 (en) 2018-03-13 2019-09-19 Ose Immunotherapeutics Use of anti-human sirpa v1 antibodies and method for producing anti-sirpa v1 antibodies
EP3768314A4 (en) 2018-03-21 2022-01-05 ALX Oncology Inc. ANTIBODIES AGAINST ALPHA SIGNAL REGULATING PROTEIN AND METHODS OF USE
MX2020011828A (es) 2018-05-25 2021-02-09 Alector Llc Anticuerpos anti proteina alfa reguladora de se?ales (sirpa) y metodos de uso de los mismos.
KR102816742B1 (ko) 2018-07-10 2025-06-05 고쿠리츠다이가쿠호진 고베다이가쿠 항 SIRPα 항체
US12084497B2 (en) 2018-08-08 2024-09-10 Orionis Biosciences, Inc. SIRP1α targeted chimeric proteins and uses thereof
TW202028237A (zh) 2018-09-27 2020-08-01 美商西建公司 SIRPα結合蛋白及其使用方法
AU2019380503A1 (en) 2018-11-14 2021-06-03 Arch Oncology, Inc. Therapeutic SIRPα antibodies
BR112021009275A2 (pt) 2018-11-15 2022-01-04 Byondis Bv Anticorpo humanizado anti-sirp alfa ou um fragmento de ligação a antígeno do mesmo, composição farmacêutica, molécula de ácido nucleico, e, célula hospedeira.
CN113784984A (zh) 2019-03-04 2021-12-10 齐鲁普吉湾生物治疗公司 抗SIRPα抗体
EP3810197A1 (en) 2019-08-20 2021-04-28 Elpiscience (Suzhou) Biopharma, Ltd. Novel anti-sirpa antibodies
CN111635458B (zh) 2020-03-20 2026-02-17 健信生物科技(宁波)有限公司 靶向Sirpα的抗体或其抗原结合片段及其制备和应用
CN111995682B (zh) 2020-08-21 2022-05-10 博奥信生物技术(南京)有限公司 抗人SIRPα单克隆抗体及其用途
CN112010979B (zh) 2020-08-21 2022-05-10 博奥信生物技术(南京)有限公司 一种抗人SIRPα单克隆抗体及其用途
CN112574310B (zh) 2020-12-11 2023-05-05 浙江博锐生物制药有限公司 抗SIRPα抗体及其用途

Similar Documents

Publication Publication Date Title
JP2022169504A5 (enExample)
TWI701259B (zh) 4﹘1bb抗體及其製備方法和應用
CN109843927B (zh) 抗b7-h3抗体、其抗原结合片段及其医药用途
US9273136B2 (en) Fully human anti-human NKG2D monoclonal antibodies
CN113543804A (zh) 抗lilrb2抗体及其使用方法
BR112021010394A2 (pt) Anticorpo anti-4-1bb e uso do mesmo
CN110267989B (zh) 抗cd40抗体、其抗原结合片段及其医药用途
CN116239698A (zh) 双功能融合蛋白及其医药用途
JP2020504095A (ja) 抗PD−L1抗体との組み合わせのための抗Tim−3抗体
JP2020504171A (ja) 抗PD−1抗体との組み合わせのための抗Tim−3抗体
JP2018531914A (ja) CD155/TIGIT経路およびTGF−βのアンタゴニストを介してがんを処置するための組成物および方法
KR20160024391A (ko) 종양 성장 및 전이를 억제하기 위한 면역 조절 요법과 병용되는 세마포린-4d 억제성 분자의 용도
CN116693686A (zh) 抗b7-h4抗体、其抗原结合片段及其医药用途
KR20200079561A (ko) Ror1 암을 치료하고 전이를 저해하는데 이용을 위한 항체와 백신
CN107266571A (zh) 抗‑mcam抗体及相关使用方法
SG187945A1 (en) Anti-ox40 antibodies and methods of using the same
KR20100014588A (ko) 길항제 ox40 항체 및 염증성 및 자가면역 질환의 치료에서의 이의 용도
AU2013206788A1 (en) Method of providing monoclonal auto-antibodies with desired specificity
CN112969714A (zh) 抗cd40抗体、其抗原结合片段及其医药用途
CN115785272A (zh) 新型抗-SIRPa抗体及其治疗应用
US20210379194A1 (en) Binding protein-toxin conjugates comprising anthracyclines, and use thereof in immune-oncological applications
US20150125397A1 (en) Dual specific binding proteins directed against immune cell receptors and autoantigens
CA3121420A1 (en) Anti-il-27 antibodies and uses thereof
WO2022143552A1 (zh) Pd-1结合分子及其应用
CN109384845B (zh) 一种cd40单克隆抗体、其制备方法及其应用